NeOnc Technologies Holdings, Inc. reported that the dose‑escalation portion of its Phase 1/2 trial for the oral bioconjugated therapy NEO212 has reached the maximum tolerated dose of 810 mg, establishing a recommended Phase 2 dose of 610 mg. The company will begin the Phase 2a metastasis cohort at 400 mg.
Early efficacy signals were observed in the dose‑escalation groups, with indications of lasting disease control in heavily pre‑treated patients with recurrent glioblastoma and brain metastases. This marks the first clinical readout of NEO212’s oral platform and suggests the conjugate can overcome temozolomide resistance mechanisms such as MGMT‑mediated DNA repair.
The milestone moves the program closer to a pivotal Phase 2 study and could accelerate regulatory review for a novel oral therapy targeting central nervous system malignancies. By validating the oral bioconjugated platform, NeOnc expands its delivery technology beyond its established intranasal system, potentially broadening the company’s therapeutic portfolio.
"These early efficacy signals, observed even within a dose‑escalation safety study, provide meaningful clinical validation of NEO212’s therapeutic potential," said Amir Heshmatpour, Chairman and CEO. "With RP2D now established, we believe NeOnc is entering Phase 2 with positive clinical momentum and a clear development pathway," he added. Dr. Thomas Chen, Vice‑Chairman and Chief Medical Officer, noted that the 610‑mg dose "confirms that our bio‑conjugation technology allows for high‑dose delivery of therapeutic agents with a manageable toxicity profile," and that the company is now positioned to explore efficacy in the upcoming Phase 2 expansion.
NeOnc’s financial profile remains challenging, with negative margins, a distressed Altman Z‑Score, and a high price‑to‑sales ratio of 3,060. The company recently secured a $10 million PIPE investment from Cinctive Capital Management. As of March 4, the stock trades at $9.40 with a market capitalization of $213.31 million, reflecting investor caution despite the positive clinical data.
NEO212 is a conjugate of temozolomide and NEO100, designed to overcome resistance mechanisms such as MGMT‑mediated DNA repair. Preclinical studies suggest superior therapeutic activity compared to temozolomide alone, positioning NEO212 as a potential replacement in the standard Stupp protocol for glioblastoma.
The dose‑escalation success and early efficacy signals provide a strong foundation for the next phase of development, but the company’s financial headwinds underscore the need for continued capital support as it advances toward regulatory approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.